Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 2/20 | 0.44 |
| ▸ | ADH1C | P00326 | 2/20 | 0.44 |
| ▸ | ADH1A | P07327 | 2/20 | 0.44 |
| ▸ | ADH7 | P40394 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ADH4 | P08319 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7889591 | 0.83 | TSHR (0.49) | CYP2D6ALDH1A1SMN1; SMN2ADH1BADH1C | |
| SCHEMBL10314666 | 0.79 | CYP2D6 (0.71) | CYP2D6ALDH1A1SMN1; SMN2DHODHNPSR1 | |
| SCHEMBL13885625 | 0.79 | HPGD (0.47) | CYP2D6ALDH1A1SMN1; SMN2DHODHNPSR1 | |
| SCHEMBL3956082 | 0.79 | ALDH1A1 (0.43) | CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1 | |
| SCHEMBL28944281 | 0.78 | EPHX1 (0.45) | CYP2D6ALDH1A1SMN1; SMN2ADH1BADH1C | |
| SCHEMBL16110273 | 0.78 | CYP1A2 (0.52) | CYP2D6ALDH1A1SMN1; SMN2ADH1BADH1C | |
| SCHEMBL7882683 | 0.77 | EPHX1 (0.50) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL27790849 | 0.76 | CYP2D6 (1.00) | CYP2D6ALDH1A1SMN1; SMN2DHODHNPSR1 | |
| SCHEMBL16935734 | 0.74 | EPHX1 (0.47) | NPSR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL23617086 | 0.73 | TSHR (0.47) | CYP2D6ALDH1A1SMN1; SMN2DHODHNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384958-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2005-05-26 | — | — | US | disclosed |
| US-6835737-B2 | For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2003-12-04 | — | — | US | disclosed |
| US-6576644-B2 | Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP) | BRISTOL-MYERS SQUIBB CO. | 2003-06-10 | — | — | US | disclosed |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | disclosed |
| WO-2002020489-A2 | QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| US-6194493-B1 | STABILILZATION OF ORGANIC MATERIALS, PHOTOSTABILITY | CLARIANT GMBH (DE) | 2001-02-27 | — | — | US | disclosed |
| EP-0900824-A1 | 4-Hydroxyquinoline-3-carboxylic acid derivatives as light stabilizers | Clariant GmbH (DE) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP2D6 1122/4885ALDH1A1 525/4885SMN1; SMN2 2619/4885 |
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP2D6 1122/4885ALDH1A1 525/4885SMN1; SMN2 2619/4885 |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP2D6 1568/4885ALDH1A1 301/4885SMN1; SMN2 2361/4885 |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP2D6 1122/4885ALDH1A1 525/4885SMN1; SMN2 2619/4885 |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE2A, PDE3A | CYP2D6 2769/4885ALDH1A1 709/4885SMN1; SMN2 3333/4885 |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP2D6 1122/4885ALDH1A1 525/4885SMN1; SMN2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.